Form 4: ALX Oncology Director Jaume Pons Executes Stock Options and Sells Shares

Jaume Pons, President & CSO and Director of ALX Oncology Holdings Inc., exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 16, 2024, Jaume Pons, a Director and the President & CSO of ALX Oncology Holdings Inc., exercised options to acquire 25,846 shares of common stock at a price of $0.99 per share.
• Simultaneously, Pons sold 50,000 shares of common stock at a weighted average price of $14.2039, with individual sales prices ranging from $14.00 to $14.47.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 6, 2023.
• Following these transactions, Pons directly owns 604,205 shares of ALX Oncology common stock and holds options for 204,433 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports insider trading activity. The use of a 10b5-1 plan suggests pre-planned transactions, reducing potential negative interpretations.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company executives and directors, which is important for investors to assess management's confidence in the company's prospects. The use of a pre-arranged Rule 10b5-1 trading plan suggests that these transactions were planned in advance and not based on any material non-public information.

Comparison to Industry Standards

• Insider transactions are common in publicly traded companies, and the reporting requirements are standardized by the SEC.
• The use of Rule 10b5-1 trading plans is a common practice among executives to avoid accusations of insider trading.
• Comparable companies such as Gilead, Amgen, and Regeneron also have executives who regularly file Form 4s to report their transactions.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates